These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 23353642)

  • 21. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
    Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ; Zhang YX; Wei H; Jia Q
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment.
    Delbeke D; Pinson CW
    J Hepatobiliary Pancreat Surg; 2004; 11(1):4-10. PubMed ID: 15747028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lower maximum standardized uptake value of fluorine-18 fluorodeoxyglucose positron emission tomography coupled with computed tomography imaging in pancreatic ductal adenocarcinoma patients with diabetes.
    Chung KH; Park JK; Lee SH; Hwang DW; Cho JY; Yoon YS; Han HS; Hwang JH
    Am J Surg; 2015 Apr; 209(4):709-16. PubMed ID: 25616974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of dynamic contrast-enhanced magnetic resonance imaging in the differentiation of pancreatic ductal adenocarcinoma from other pancreatic solid lesions.
    Liu K; Xie P; Peng W; Zhou Z
    J Comput Assist Tomogr; 2014; 38(5):681-6. PubMed ID: 24943251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of fluorodeoxyglucose and positron emission tomography in the evaluation of pancreatic disease.
    Rajput A; Stellato TA; Faulhaber PF; Vesselle HJ; Miraldi F
    Surgery; 1998 Oct; 124(4):793-7; discussion 797-8. PubMed ID: 9781003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of baseline positron emission tomography with computed tomography for predicting endoscopic resectability and survival outcomes in patients with early esophageal adenocarcinoma.
    Sun G; Tian J; Gorospe EC; Johnson GB; Hunt CH; Lutzke LS; Leggett CL; Iyer PG; Wang KK
    J Gastroenterol Hepatol; 2013 Jun; 28(6):975-81. PubMed ID: 23425230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The differentiation of autoimmune pancreatitis and pancreatic cancer using imaging findings.
    Shin JU; Lee JK; Kim KM; Lee KH; Lee KT; Kim YK; Lim JH; Jang KT
    Hepatogastroenterology; 2013; 60(125):1174-81. PubMed ID: 24298613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of diagnostic performance between CT and MRI in differentiating non-diffuse-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma.
    Lee S; Kim JH; Kim SY; Byun JH; Kim HJ; Kim MH; Lee MG; Lee SS
    Eur Radiol; 2018 Dec; 28(12):5267-5274. PubMed ID: 29948075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Differentiation of autoimmune pancreatitis and pancreatic ductal adenocarcinoma based on multi-modality texture features in
    Zhang Y; Cheng C; Liu Z; Pan G; Sun G; Yang X; Zuo C
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2019 Oct; 36(5):755-762. PubMed ID: 31631623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging diagnosis of post-ERCP focal pancreatitis mimicking pancreatic carcinoma by follow-up F-18 FDG PET/CT.
    Jeong Yoon S; Lee B; Park CH
    Clin Nucl Med; 2011 Jan; 36(1):70-2. PubMed ID: 21157219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer.
    Ghaneh P; Hanson R; Titman A; Lancaster G; Plumpton C; Lloyd-Williams H; Yeo ST; Edwards RT; Johnson C; Abu Hilal M; Higginson AP; Armstrong T; Smith A; Scarsbrook A; McKay C; Carter R; Sutcliffe RP; Bramhall S; Kocher HM; Cunningham D; Pereira SP; Davidson B; Chang D; Khan S; Zealley I; Sarker D; Al Sarireh B; Charnley R; Lobo D; Nicolson M; Halloran C; Raraty M; Sutton R; Vinjamuri S; Evans J; Campbell F; Deeks J; Sanghera B; Wong WL; Neoptolemos JP
    Health Technol Assess; 2018 Feb; 22(7):1-114. PubMed ID: 29402376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer.
    Lee TY; Kim MH; Park DH; Seo DW; Lee SK; Kim JS; Lee KT
    AJR Am J Roentgenol; 2009 Aug; 193(2):343-8. PubMed ID: 19620430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differentiating focal autoimmune pancreatitis and pancreatic ductal adenocarcinoma: contrast-enhanced MRI with special emphasis on the arterial phase.
    Kwon JH; Kim JH; Kim SY; Byun JH; Kim HJ; Lee MG; Lee SS
    Eur Radiol; 2019 Nov; 29(11):5763-5771. PubMed ID: 31028441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer.
    Imdahl A; Nitzsche E; Krautmann F; Högerle S; Boos S; Einert A; Sontheimer J; Farthmann EH
    Br J Surg; 1999 Feb; 86(2):194-9. PubMed ID: 10100786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The value of fluorodeoxyglucose positron emission tomography (FDG-PET) in differentiation of pancreatic lesions].
    Voth M; Opfermann T; Gottschild D
    Zentralbl Chir; 2003 May; 128(5):375-8. PubMed ID: 12813634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Fluorodeoxyglucose positron emission tomography (FDG-PET) in the differential diagnosis of pancreatic lesions].
    Zimny M; Schumpelick V
    Chirurg; 2001 Sep; 72(9):989-94. PubMed ID: 11594284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of EUS in relation to other imaging modalities in the differential diagnosis between mass forming chronic pancreatitis, autoimmune pancreatitis and ductal pancreatic adenocarcinoma.
    Iglesias-García J; Lindkvist B; Lariño-Noia J; Domínguez-Muñoz JE
    Rev Esp Enferm Dig; 2012 Jun; 104(6):315-21. PubMed ID: 22738702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypermetabolic lesions of the pancreas on FDG PET/CT.
    Dong A; Dong H; Zhang L; Zuo C
    Clin Nucl Med; 2013 Sep; 38(9):e354-66. PubMed ID: 23486316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.